UK first major European country to run Zostavax shingles vaccination program

22 January 2013

The UK has decided to launch the first-ever national shingles immunization campaign in Europe using the innovative Zostavax (live varicella zoster vaccine ) vaccine from Sanofi Pasteur MSD, the joint venture in Europe between US drug giant Merck & Co (NYSE: MRK) and Sanofi Pasteur, a subsidiary of France’s Sanofi (Euronext: SAN).

Eligible senior members of the public will be able to receive the Zostavax vaccine during regular health visits or at the same time as their seasonal flu jab. The decision from the UK's Department of Health follows a comprehensive assessment of the health and economic benefits of shingles vaccination.

Zostavax is the first and only vaccine available for the prevention of shingles and the long lasting nerve pain that may follow the disease, known as post herpetic neuralgia. The vaccine is licensed in Europe for immunization of adults over 50 years - immunocompetent adults (SmPC) - and can be given as a single injection.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK